CM
APRE icon

Crestline Management’s Aprea Therapeutics APRE Stock Holding History

Crestline Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,441
Closed -$36K – 209
2022
Q2 		$36K Sell
2,441
-32
-1% -$738 ﹤0.01% 219
2022
Q1 		$92K Buy
+2,473
New +$101K 0.01% 246

Other funds holding APRE

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Crestline Management's APRE Position: Q3 2022 in Review

Crestline Management sold out of Aprea Therapeutics (APRE) in Q3 2022, closing a stake of 2,441 shares — an estimated $36K sold.

Crestline Management first reported a position in APRE in Q1 2022 and held it in 2 quarters. The position peaked at $92K in Q1 2022. 26 funds tracked by Wall St. Rank hold APRE as of Q3 2022.

  • Crestline Management reported no remaining Aprea Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 2,441 Aprea Therapeutics shares in Q3 2022, an estimated $36K.
  • Crestline Management first reported a position in Aprea Therapeutics in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Aprea Therapeutics position peaked at $92K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.